Evidence map›Paper›PMID 40579211›Full record

ArticleJNCI cancer spectrum2025

Risk of early death after acute leukemia diagnosis among adolescents and young adults.

Amy M Berkman, Clark R Andersen, Vidya Puthenpura, Nicholas J Short, Kelly Merriman, Mahesh Swaminathan, Branko Cuglievan, David McCall, Courtney DiNardo, Cesar Nunez and 9 more

Abstract read
In one paragraph

Article in JNCI cancer spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Amy M BerkmanDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105, United States.ORCID 0000-0003-0650-3664
Clark R AndersenDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.ORCID 0000-0003-1846-9117
Vidya PuthenpuraSection of Pediatric Hematology and Oncology, Department of Pediatrics, Yale School of Medicine, New Haven, CT 06510, United States.ORCID 0000-0002-9829-5841
Nicholas J ShortDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Kelly MerrimanDepartment of Cancer Registry, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Mahesh SwaminathanDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.ORCID 0000-0001-5959-397X
Branko CuglievanDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
David McCallDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.ORCID 0000-0003-2297-9670
Courtney DiNardoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.ORCID 0000-0001-9003-0390
Cesar NunezDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.ORCID 0000-0002-9701-8826
Nitin JainDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.ORCID 0000-0003-0114-8384
Tapan KadiaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.ORCID 0000-0002-9892-9832
Ghayas IssaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.ORCID 0000-0002-4339-8683
Amber GibsonDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.ORCID 0000-0002-9146-4702
Miriam B GarciaDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.ORCID 0000-0002-2978-2267
J Andrew LivingstonDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.ORCID 0000-0002-1337-3282
Susan ParsonsDivision of Hematology/Oncology and Institute for Clinical Research and Health Policy Studies, Tufts Medical Center Cancer Center, Boston, MA 02111, United States.ORCID 0000-0003-0282-6490
Michelle A T HildebrandtDepartment of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.ORCID 0000-0001-6769-6872
Michael E RothDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.ORCID 0000-0002-6411-8353

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672NIH HHS
6 · The paper itself

Abstract

backgroundAdvances in care have led to improvements in survival for adolescents and young adults (AYAs) diagnosed with cancer; however, the risk of early death remains high for certain cancers, particularly acute leukemias. Risk factors for early death in AYAs diagnosed with acute leukemia have not been well studied.

methodsThe Surveillance, Epidemiology, and End Results registry was used to assess risk of early death (within 2 months of diagnosis) in AYAs diagnosed with acute leukemia (n = 16 153). Early death proportion, by year, for AYAs diagnosed between 2006 and 2020 was described. Associations between incidence of early death and age at diagnosis, sex, race and ethnicity, socioeconomic status, rurality, acute leukemia type, and year of diagnosis were evaluated with logistic regression.

resultsOverall, 6.0% of AYAs experienced early death and there was a significant annual decrease in the odds of early death (odds ratio [OR] = 0.96, 95% confidence interval [CI] = 0.95 to 0.98, P < .0001) across the study period. Over the entire study period, AYAs diagnosed with acute promyelocytic leukemia (9.6%, 95% CI = 8.4 to 11.1) or other acute leukemias (13.3%, 95% CI = 10.5 to 16.7) had the highest proportion of early death and AYAs diagnosed with T lymphoblastic leukemia/lymphoma had the lowest (2.6%, 95% CI = 1.9 to 3.7). Older age at diagnosis, male sex, and Hispanic ethnicity were all associated with increased risk of early death.

conclusionsA high proportion of AYAs with acute leukemia experience early death and risk varies by leukemia type and sociodemographic factors. A better understanding of the complex interplay between disease biology and sociodemographic factors is needed to guide risk prediction and prevention.

Indexed as

LeukemiaLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaAdolescentAdultAge FactorsFemaleHumansIncidenceLeukemia, Promyelocytic, AcuteLogistic ModelsMalePrecursor T-Cell Lymphoblastic Leukemia-LymphomaRisk FactorsSEER ProgramSex Factors

Identifiers

PMID40579211
PMCPMC12231595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.